Exchange: NASDAQ·Updated 07:42 PM EDT
PROF logo

PROF Profound Medical Corp

$6.88
$0.01
(0.14%)
Today
Closed $6.90
$0.0199
(0.29%)
After Hours
EarningsNov 5
Mkt Cap$252.07M
Vol428,720.00

About PROF

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm’s product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.
79

Extremely Bullish Sentiment

How do you feel about PROF?

focafoca99
$PROF released its preliminary unaudited Q3 2026 results for the three months ended Sep 30, 2026.
2
Stef_Gee
$PROF $3.1 million of TULSA revenue had shifted into Q3 because of shipment timing, so of the $9.8M / $10M expected Q3 revenue, $3.1M was already identified in August as delayed shipments. That's 31% of the expected Q3 revenue + yesterday's preliminary Q3 release did not announce a higher annual forecast
1
bizness1957
$PROF According to the 5 industry analysts covering Profound Medical, the consensus is that breakeven is near. They expect the company to post a final loss in 2027, before turning a profit of US$9.4m in 2028.
bizness1957
$PROF baby boomers are large market 13% .. Prostate cancer incidence increases sharply with age, with roughly 60% of cases diagnosed in men aged 65 and older and an average age at diagnosis of 66 to 68 years. Breakdown by Age Group • Under 50 years: Prostate cancer is rare in this group, occurring in about 1 in 350 to 1 in 500 men (less than 5% of all cases). • Ages 45–54: Accounts for roughly 5% of U.S. cases. • Ages 55–69: Accounts for the majority of diagnoses—approximately 52% to 70% of cases depending on specific federal reporting tiers. • Ages 70 and older: Accounts for about 43% of cases, and the risk of harboring subclinical prostate cancer exceeds 50% in men in their 80s and 90s. • Lifetime Risk: Overall, about 1 in 8 men (13.2%) will be diagnosed with prostate cancer during their lifetime.
bizness1957
$PROF Profound Medical Corp (NASDAQ:PROF) is seeing accelerating commercial momentum, evidenced by a record month for new orders in July, a qualified sales pipeline of approximately $70 million, and over 160 qualified leads generated at the SRS 2026 conference.
GSP
$PROF 25m float: Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
DayTrade_4Life
🔥Some Stocks to Watch for 8 Oct: AIXI MRNO IPW OLB $PROF $SMXT $XRPN 💵Below are today's results and this month's Top Alerts. 👉See Profile to Join Us.
johntarlick
$PROF crikey, driver is out too? that guy has been around for some years in engineering management, much longer than vertuccio, and i think he made it to vp of product development or something. How in the heck does someone with that track record bail now?
johntarlick
$PROF crikey, vertuccio is out too? she was hand-picked by the CCO to lead the marketing as he rebuilt the scorched earth from the ground up, and amongst other things she lead the initiative to get the nfl guy as a spokesperson for the brand. how does she pack up and leave just a year later?

Advertisement|Remove ads.